FDA Accepts Biologics License Application for Sobi's NASP for Patients with Uncontrolled Gout

Swedish Orphan Biovitrum AB Sweden

Submission includes results of the pivotal DISSOLVE I and II studiesNASP PDUFA date set for 27 June 2026View original content:https://www.prnewswire.co.uk/news-releases/fda-accepts-biologics-license-application-for-sobis-nasp-for-patients-with-uncontrolled-gout-302552102.html